In Korea, health insurance covers the administration of G-CSF for therapeutic use only when patients treated with chemotherapy have agranulocytosis (ANC < 500 cells/mm3) or neutropenia (ANC < 1000 cells/mm3) with fever. The gene discussed is CSF3; the disease is neutropenia.